3-(3,4-dichlorophenyl)-1,2,4-thiadiazol-5-amine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(3,4-dichlorophenyl)-1,2,4-thiadiazol-5-amine
• 化学式: C₈H₅Cl₂N₃S
• 分子量: 246.12
• InChiKey: ZLKLABQQOFZPPR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  80
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-(3,4-dichlorophenyl)-1,2,4-thiadiazol-5-amine 、 吉非替尼中间体3 在 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 20.0h， 以15 mg的产率得到2-cyano-N-[3-(3,4-dichlorophenyl)-1,2,4-thiadiazol-5-yl]acetamide
  参考文献：
  名称：

  使用片段和HTS方法论鉴定和优化新型小型c-Abl激酶激活剂。

  摘要：

  Abelson激酶（c-Abl）是一种普遍表达的非受体酪氨酸激酶，在细胞分化和存活中起关键作用。据推测，通过N-末端自抑制“肉豆蔻酰闩锁”的移位，瞬时激活c-Abl激酶可能导致造血干细胞分化增加。这将增加循环中性粒细胞的数量，因此是化疗诱发的中性粒细胞减少症的有效治疗方法。本文介绍了噻唑系列新型小分子c-Abl激活剂的发现和优化，该试剂最初通过高通量筛选得以鉴定。随后，利用片段筛选筛选方法开发的二氢吡唑类似物的改善的理化特性，进行了脚手架跳，并提供了有效的，可溶的，具有细胞活性的c-Abl活化剂，

  DOI：

  10.1021/acs.jmedchem.8b01872
• 作为产物：
  描述：

  potassium thioacyanate 、 3,4-二氯苯甲酰胺 在 溴 作用下， 生成 3-(3,4-dichlorophenyl)-1,2,4-thiadiazol-5-amine
  参考文献：
  名称：

  Pyrimidine benzamide-based thrombopoietin receptor agonists

  摘要：

  A series of pyrimidine benzamide-based thrombopoietin receptor agonists is described. The lead molecule contains a 2-amino-5-unsubstituted thiazole, a group that has been associated with idiosyncratic toxicity. The potential for metabolic oxidation at C-5 of the thiazole, the likely source of toxic metabolites, was removed by substitution at C-5 or by replacing the thiazole with a thiadiazole. Potency in the series was improved by modifying the substituents on the pyrimidine and/or on the thiazole or thiadiazole pendant aryl ring. In vivo examination revealed that compounds from the series are not highly bioavailable. This is attributed to low solubility and poor permeability. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.07.038

文献信息

• Substituted 5-amino-1,2,4-thiadiazoles with pharmaceutical activity
  申请人：LILLY INDUSTRIES LIMITED

  公开号：EP0455356A1

  公开（公告）日：1991-11-06

  Pharmaceutical compounds of the following formula are described: in which R¹ is hydrogen, C₁₋₄ alkyl, C₁₋₄ alkoxy-C₁₋₄ alkyl, hydroxy-C₁₋₄ alkyl, optionally substituted phenyl, optionally substituted phenyl-C₁₋₄ alkyl or a heterocycle selected from: where R³ is hydrogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, nitro, halo, cyano, trifluoromethyl, carboxyl or -CONH₂, and R⁴ is C₁₋₄ alkyl; and R² is hydrogen, C₁₋₄ alkyl, phenyl or thienyl substituted with a carboxyl or C₁₋₄ alkoxy-carbonyl group, an acyl group of the formula R⁵CO- where R⁵ is hydrogen, C₁₋₄ alkyl, C₁₋₄ alkoxy-C₁₋₄ alkyl, halo C₁₋₄ alkyl, C₁₋₄ alkoxy, halo-C₁₋₄ alkoxy, phenyl, phenyl-C₁₋₄ alkyl, -NHC₁₋₄ alkyl, -NH phenyl or where R⁶ is C₁₋₄ alkyl, or a group of the formula -CH=C(COC₁₋₄ alkoxy)₂; or a salt thereof.

  以下是描述的具有以下结构的药物化合物： 其中R¹为氢、C₁₋₄烷基、C₁₋₄烷氧基-C₁₋₄烷基、羟基-C₁₋₄烷基、可选择取代的苯基、可选择取代的苯基-C₁₋₄烷基或从以下选取的杂环： 其中R³为氢、C₁₋₄烷基、C₁₋₄烷氧基、硝基、卤素、氰基、三氟甲基、羧基或-CONH₂，R⁴为C₁₋₄烷基；而R²为氢、C₁₋₄烷基、苯基或经羧基或C₁₋₄烷氧基羰基取代的噻吩基，具有R⁵CO-式的酰基，其中R⁵为氢、C₁₋₄烷基、C₁₋₄烷氧基-C₁₋₄烷基、卤素C₁₋₄烷基、C₁₋₄烷氧基、卤素-C₁₋₄烷氧基、苯基、苯基-C₁₋₄烷基、-NHC₁₋₄烷基、-NH苯基或 其中R⁶为C₁₋₄烷基，或具有-CH=C(COC₁₋₄烷氧基)₂式的基团；或其盐。
• Pyrimidine benzamide-based thrombopoietin receptor agonists
  作者：Lawrence A. Reiter、Chakrapani Subramanyam、Emilio J. Mangual、Christopher S. Jones、Marc I. Smeets、William H. Brissette、Sandra P. McCurdy、Paul D. Lira、Robert G. Linde、Qifang Li、Fangning Zhang、Amy S. Antipas、Laura C. Blumberg、Jonathan L. Doty、James P. Driscoll、Michael J. Munchhof、Sharon L. Ripp、Andrei Shavnya、Richard M. Shepard、Diana Sperger、Lisa M. Thomasco、Kristen A. Trevena、Lilli A. Wolf-Gouveia、Liling Zhang

  DOI：10.1016/j.bmcl.2007.07.038

  日期：2007.10

  A series of pyrimidine benzamide-based thrombopoietin receptor agonists is described. The lead molecule contains a 2-amino-5-unsubstituted thiazole, a group that has been associated with idiosyncratic toxicity. The potential for metabolic oxidation at C-5 of the thiazole, the likely source of toxic metabolites, was removed by substitution at C-5 or by replacing the thiazole with a thiadiazole. Potency in the series was improved by modifying the substituents on the pyrimidine and/or on the thiazole or thiadiazole pendant aryl ring. In vivo examination revealed that compounds from the series are not highly bioavailable. This is attributed to low solubility and poor permeability. (C) 2007 Elsevier Ltd. All rights reserved.
• Identification and Optimization of Novel Small c-Abl Kinase Activators Using Fragment and HTS Methodologies
  作者：Graham L. Simpson、Sophie M. Bertrand、Jennifer A. Borthwick、Nino Campobasso、Julien Chabanet、Susan Chen、Julia Coggins、Josh Cottom、Siegfried B. Christensen、Helen C. Dawson、Helen L. Evans、Andrew N. Hobbs、Xuan Hong、Biju Mangatt、Jordi Munoz-Muriedas、Allen Oliff、Donghui Qin、Paul Scott-Stevens、Paris Ward、Yoshiaki Washio、Jingsong Yang、Robert J. Young

  DOI：10.1021/acs.jmedchem.8b01872

  日期：2019.2.28

  hypothesized that transient activation of c-Abl kinase via displacement of the N-terminal autoinhibitory "myristoyl latch", may lead to an increased hematopoietic stem cell differentiation. This would increase the numbers of circulating neutrophils and so be an effective treatment for chemotherapy-induced neutropenia. This paper describes the discovery and optimization of a thiazole series of novel small molecule

  Abelson激酶（c-Abl）是一种普遍表达的非受体酪氨酸激酶，在细胞分化和存活中起关键作用。据推测，通过N-末端自抑制“肉豆蔻酰闩锁”的移位，瞬时激活c-Abl激酶可能导致造血干细胞分化增加。这将增加循环中性粒细胞的数量，因此是化疗诱发的中性粒细胞减少症的有效治疗方法。本文介绍了噻唑系列新型小分子c-Abl激活剂的发现和优化，该试剂最初通过高通量筛选得以鉴定。随后，利用片段筛选筛选方法开发的二氢吡唑类似物的改善的理化特性，进行了脚手架跳，并提供了有效的，可溶的，具有细胞活性的c-Abl活化剂，